Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEXAPRO vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder (off-label),Panic disorder (off-label),Post-traumatic stress disorder (off-label),Premenstrual dysphoric disorder (off-label)
Mild to moderate pain,Pain accompanied by fever
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (Cr Cl <20 m L/min).
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Initial 5 mg orally once daily; maximum 10 mg once daily.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Suicidality risk in young adults,Serotonin syndrome,QT prolongation,Hyponatremia,Bleeding risk,Activation of mania/hypomania,Seizure risk,Abrupt discontinuation syndrome
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Concomitant use of pimozide,Hypersensitivity to escitalopram or citalopram,QT prolongation or congenital long QT syndrome (for citalopram, caution for escitalopram)
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Escitalopram is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 2.0. Infant serum levels are typically low, but some cases of adverse effects such as irritability, feeding problems, and sleep disturbance have been reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding, but caution is advised, especially in premature or compromised infants.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Pharmacokinetic changes during pregnancy (increased volume of distribution, increased clearance) may require dose adjustments. Escitalopram clearance increases by approximately 50% in the third trimester. Dose increases may be needed to maintain efficacy, with gradual reduction postpartum to pre-pregnancy dose over 2-4 weeks. Therapeutic drug monitoring of escitalopram and its metabolite S-DCT is recommended if available, targeting trough levels of 15-80 ng/m L.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Take LEXAPRO once daily, either in the morning or evening, consistently with or without food.,Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners.,Avoid alcohol and grapefruit juice as they may increase side effects.,Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting).,It may take several weeks to feel the full benefit; continue taking as prescribed.,Monitor for worsening depression or anxiety, especially during the first few months of treatment.,If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications).
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEXAPRO vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
LEXAPRO is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEXAPRO and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEXAPRO is: 10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEXAPRO and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEXAPRO is classified as Category C. First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk o. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.